[1]姜如华.美托洛尔联合烟酰胺治疗心力衰竭合并心律失常的效果及对患者心功能的影响[J].医学信息,2024,37(10):126-129.[doi:10.3969/j.issn.1006-1959.2024.10.026]
　JIANG Ru-hua.Effect of Metoprolol Combined with Nicotinamide in the Treatment of Heart Failure Complicated with Arrhythmia and its Influence on Cardiac Function[J].Journal of Medical Information,2024,37(10):126-129.[doi:10.3969/j.issn.1006-1959.2024.10.026]
点击复制

美托洛尔联合烟酰胺治疗心力衰竭合并心律失常的效果及对患者心功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年10期
页码:
126-129
栏目:
论著
出版日期:
2024-05-15

文章信息/Info

Title:
Effect of Metoprolol Combined with Nicotinamide in the Treatment of Heart Failure Complicated with Arrhythmia and its Influence on Cardiac Function
文章编号:
1006-1959（2024）10-0126-04
作者:
姜如华
（广丰和祥医院心血管内科，江西 上饶 334699）
Author(s):
JIANG Ru-hua
(Department of Cardiovascular Medicine,Guangfeng Hexiang Hospital,Shangrao 334699,Jiangxi,China)
关键词:
心力衰竭; 心律失常; 美托洛尔; 烟酰胺; 心功能
Keywords:
Heart failure; Arrhythmias; Metoprolol; Nicotinamide; Cardiac function
分类号:
R541.7；R541.6
DOI:
10.3969/j.issn.1006-1959.2024.10.026
文献标志码:
A
摘要:
目的 研究美托洛尔联合烟酰胺治疗心力衰竭（HF）合并心律失常的临床效果及对患者心功能的影响。方法 以2020年11月-2022年11月广丰和祥医院收治的60例HF合并心律失常患者为研究对象，经随机数字表法分为对照组（30例）与观察组（30例）。对照组给予美托洛尔治疗，观察组在其基础上联合烟酰胺治疗，比较两组临床疗效、心功能[左室射血分数（LVEF）、左室舒张末期内径（LVEDD）、左室收缩末期内径（LVESD）]、心律失常发作情况（发作频率、持续时间）、Memorial心力衰竭症状评估量表（MSAS-HF）评分及不良反应。结果 观察组总有效率（93.33%）高于对照组（76.67%）（P＜0.05）。两组治疗后LVEF大于治疗前，LVEDD、LVESD小于治疗前，且观察组LVEF大于对照组，LVEDD、LVESD小于对照组（P＜0.05）。两组治疗后心律失常发作频率、持续时间少于治疗前，且观察组心律失常发作频率、持续时间少于对照组（P＜0.05）。两组治疗后MSAS-HF评分低于治疗前，且观察组MSAS-HF评分低于对照组（P＜0.05）。两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 美托洛尔联合烟酰胺治疗HF合并心律失常效果确切，可改善患者心功能，减少心律失常发作频率和时间，缓解心衰症状，且不增加药物不良反应，安全性良好。
Abstract:
Objective To study the clinical effect of metoprolol combined with nicotinamide in the treatment of heart failure (HF) complicated with arrhythmia and its effect on cardiac function.Methods A total of 60 patients with HF complicated with arrhythmia admitted to Guangfeng Hexiang Hospital from November 2020 to November 2022 were divided into control group (30 patients) and observation group (30 patients) by random number table method. The control group was treated with metoprolol, and the observation group was treated with nicotinamide on the basis of the control group. The clinical efficacy, cardiac function [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD)], arrhythmia attack (frequency and duration of attack), Memorial Symptom Assessment Scale-Heart Failure (MSAS-HF) score and adverse reactions were compared between the two groups.Results The total effective rate of the observation group (93.33%) was higher than that of the control group (76.67%) (P<0.05). After treatment, LVEF in the two groups was higher than that before treatment, LVEDD and LVESD were lower than those before treatment, and LVEF in the observation group was higher than that in the control group, LVEDD and LVESD were lower than those in the control group (P<0.05). After treatment, the frequency and duration of arrhythmia in the two groups were less than those before treatment, and the frequency and duration of arrhythmia in the observation group were less than those in the control group (P<0.05). After treatment, the MSAS-HF score of the two groups was lower than that before treatment, and the MSAS-HF score of the observation group was lower than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Metoprolol combined with nicotinamide is effective in the treatment of HF complicated with arrhythmia, which can improve the cardiac function of patients, reduce the frequency and time of arrhythmia, relieve the symptoms of heart failure, and do not increase the adverse drug reactions, with good safety.

参考文献/References:

[1]时彬,卢运,魏晶晶.酒石酸美托洛尔联合贝那普利对高血压合并心力衰竭患者心功能指标、血压昼夜节律变化及心率变异性的影响[J].中南医学科学杂志,2022,50(1):93-97.[2]谢美莎.美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效及其对患者心功能及炎性反应的影响研究[J].贵州医药,2021,45(10):1602-1603.[3]王红霞.胺碘酮联合美托洛尔治疗冠心病合并心律失常临床疗效及不良反应发生率分析[J].中国药物与临床,2021,21(8):1359-1361.[4]张志敏,高淑梅,侯瑞田,等.美托洛尔联合胺碘酮治疗慢性心力衰竭合并室性心律失常患者的临床研究[J].中国临床药理学杂志,2020,36(10):1180-1182,1190.[5]周海涛,毕剑波,张定国.美托洛尔联合伊伐布雷定对重度心力衰竭合并窦性心动过速患者心功能的影响[J].心脑血管病防治,2020,20(5):460-463.[6]何伟喜,彭金华,徐小华.替罗非班联合烟酰胺注射液对急性心肌梗死患者疗效观察及对心肌酶的影响[J].天津药学,2023,35(1):50-53.[7]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.[8]中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会.2020室性心律失常中国专家共识(2016共识升级版)[J].中华心律失常学杂志,2020,24(3):188-258.[9]杨小密,王凤莉.美托洛尔联合胺碘酮治疗冠心病慢性心力衰竭患者室性心律失常的研究[J].药物评价研究,2019,42(9):1789-1793.[10]黎云,高日扬,林小亮,等.厄贝沙坦联合美托洛尔治疗慢性心力衰竭合并房性或室性心律失常患者的疗效[J].心血管康复医学杂志,2019,28(4):466-469.[11]杨敏.曲美他嗪和美托洛尔联合治疗冠心病心力衰竭对临床疗效心功能和生活质量的影响[J].山西医药杂志,2019,48(16):2042-2044.[12]梁国君,廖桂华.美托洛尔联合曲美他嗪对老年高血压合并慢性心力衰竭患者的疗效[J].中国医药,2019,14(2):179-182.[13]张娇,许鹏,张清涛,等.胺碘酮联合美托洛尔治疗冠心病合并心律失常临床效果观察[J].解放军医药杂志,2018,30(10):70-72.[14]夏雷风,谢宗贤,裴杰,等.胺碘酮联合美托洛尔对心律失常病人心功能和心肌标志物的影响[J].中西医结合心脑血管病杂志,2018,16(18):2673-2677.[15]王冠男,李勇,张健,等.美托洛尔联合胺碘酮治疗冠心病合并心律失常的临床疗效观察[J].中华老年心脑血管病杂志,2018,20(9):932-935.[16]Larocque EA,Naganna N,Opoku‐Temeng C,et al.Alkynylnicotinamide‐Based Compounds as ABL1 Inhibitors with Potent Activities against Drug‐Resistant CML Harboring ABL1(T315I) Mutant Kinase[J].ChemMedChem,2018,13(12):1172-1180.[17]Zihui Y,Ling G,Cong Z,et al.Synthesis and biological evaluation of nicotinamide derivatives with a diarylamine-modified scaffold as succinate dehydrogenase inhibitors[J].Journal of Pesticide Science,2020,45(2):48.[18]朱丹桂,陈晶,杜晓马,等.胺碘酮联合美托洛尔治疗冠心病合并心律失常效果评估[J].中国药物与临床,2019,19(21):3760-3761.[19]桑明敏,朱芳一,马生龙,等.胺碘酮分别联合比索洛尔与美托洛尔治疗收缩性心力衰竭合并室性心律失常效果比较[J].疑难病杂志,2018,17(8):762-766．[20]Xiao Y,Phelp P,Bakker D,et al.Only the NAD precursor nicotinamide riboside maintains cardioprotection under clinically relevant conditions, possibly through activation of glycolysis[J].European Heart Journal,2021,42(1):724.[21]Mitchell SJ,Bernier M,Aon MA,et al.Nicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice[J].Cell Metabolism,2018,27(3):667.

相似文献/References:

[1]郭俊林,张立.BNP对CRT后期疗效的临床评价[J].医学信息,2018,31(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
　GUO Jun-lin,ZHANG li.Clinical Evaluation of BNP in Treatment of Late CRT[J].Journal of Medical Information,2018,31(10):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
[2]程 林.重组人脑利钠肽用于重症急性心肌炎伴 心力衰竭患者治疗的临床研究[J].医学信息,2018,31(08):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
　CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Journal of Medical Information,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
[3]胡丽君.螺内酯联合曲美他嗪治疗慢性心力衰竭的疗效分析[J].医学信息,2018,31(08):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
　HU Li-jun.Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure[J].Journal of Medical Information,2018,31(10):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
[4]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
　LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Journal of Medical Information,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[5]黄光明,赵兴昌,符显昭.水中运动联合中药内治对糖尿病大鼠心肌细胞凋亡和心功能的影响[J].医学信息,2022,35(11):72.[doi:10.3969/j.issn.1006-1959.2022.11.020]
　HUANG Guang-ming,ZHAO Xing-chang,FU Xian-zhao.Effects of Aquatic Therapeutic Exercise Combined with Traditional Chinese Medicine Internal Treatment on Cardiomyocyte Apoptosis and Cardiac Function in Diabetic Rats[J].Journal of Medical Information,2022,35(10):72.[doi:10.3969/j.issn.1006-1959.2022.11.020]
[6]何玲玲,程淑芬.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭疗效观察[J].医学信息,2018,31(13):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
　HE Ling-ling,CHENG Shu-fen.Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure[J].Journal of Medical Information,2018,31(10):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
[7]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
　ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Journal of Medical Information,2018,31(10):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[8]施国富,吴春阳,施亚明,等.血浆脑钠肽对射血分数保留心力衰竭患者的诊断价值研究[J].医学信息,2018,31(16):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
　SHI Guo-fu,WU Chun-yang,SHI Ya-ming,et al.Diagnostic Value of Plasma Brain Natriuretic Peptide in Patients with Heart Failure Preserved by Ejection Fraction[J].Journal of Medical Information,2018,31(10):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
[9]张红新.归脾汤联合美托洛尔治疗冠心病合并心律失常的效果及预后[J].医学信息,2019,32(04):156.[doi:10.3969/j.issn.1006-1959.2019.04.051]
　ZHANG Hong-xin.Effect and Prognosis of Guipi Decoction Combined with Metoprolol in the Treatment of Coronary Heart Disease Complicated with Arrhythmia[J].Journal of Medical Information,2019,32(10):156.[doi:10.3969/j.issn.1006-1959.2019.04.051]
[10]李 宁,胡硕强.心脏再同步治疗心力衰竭的文献计量分析[J].医学信息,2018,31(19):79.[doi:10.3969/j.issn.1006-1959.2018.19.024]
　LI Ning,HU Shou-qiang.Bibliometric Analysis of Cardiac Resynchronization in the Treatment of Heart Failure[J].Journal of Medical Information,2018,31(10):79.[doi:10.3969/j.issn.1006-1959.2018.19.024]
[11]王小忠,常先松,赵良平,等.桥接整合因子1与心血管疾病的关系研究[J].医学信息,2022,35(01):46.[doi:10.3969/j.issn.1006-1959.2022.01.011]
　WANG Xiao-zhong,CHANG Xian-song,ZHAO Liang-ping,et al.Research of the Relationship Between Bridging Integrator 1 and Cardiovascular Diseases[J].Journal of Medical Information,2022,35(10):46.[doi:10.3969/j.issn.1006-1959.2022.01.011]
[12]平兰芝,黄小楼,胡天俊,等.CaMKⅡ在心血管疾病中的研究[J].医学信息,2022,35(10):59.[doi:10.3969/j.issn.1006-1959.2022.10.014]
　PING Lan-zhi,HUANG Xiao-lou,HU Tian-jun,et al.Research on the Role of CaMKⅡ in Cardiovascular Diseases[J].Journal of Medical Information,2022,35(10):59.[doi:10.3969/j.issn.1006-1959.2022.10.014]
[13]刘革铭,马洪俊,刘 毅,等.心力衰竭的机制及诊疗的研究[J].医学信息,2022,35(10):91.[doi:10.3969/j.issn.1006-1959.2022.10.022]
　LIU Ge-ming,MA Hong-jun,LIU Yi,et al.Mechanism, Diagnosis and Treatment of Heart Failure[J].Journal of Medical Information,2022,35(10):91.[doi:10.3969/j.issn.1006-1959.2022.10.022]

更新日期/Last Update: 1900-01-01